期刊文献+

魔芋葡甘聚糖/聚乙烯吡咯烷酮水凝胶的制备及缓释性能研究 被引量:8

The Preparation and Characterization of Konjac Glucomannan/Polyvinylpyrrolidone Hydrogel for Controlled Release in Vitro
下载PDF
导出
摘要 以魔芋葡甘聚糖(KGM)和聚乙烯吡咯烷酮(PVP)为原料,戊二醛(GA)为交联剂,合成了KGM/PVP半互穿网络水凝胶。通过红外光谱、X-衍射、SEM扫描电镜对水凝胶的结构进行了表征,并且研究了KGM与PVP质量比、交联剂含量对水凝胶的溶胀度影响。在pH=2.2和pH=7.4条件下分别研究了交联度对溶胀动力学特性的影响,以及载药凝胶的体外释放行为。实验结果表明,KGM与PVP质量比对该凝胶的溶胀性能有一定的影响:KGM:PVP为1:1时,凝胶的溶胀度最大;随着交联剂含量的增加,凝胶的溶胀度、溶胀速率、药物的释放速率均逐渐降低;凝胶在pH=2.2时的溶胀度较高,溶胀速率、药物的释放速率均较快。 A semi - interpenetrating polymer mlidone using glutaraldehyde as crosslinking networks hydrogel was prepared with Konjac Glucomannan and polyvinylpyragent. The structure of the semi - IPN hydrogel was studied by Fourier transform infrared spectroscopy, X - ray diffraction and scanning electron microscopy. The effect of the mass ratio of Konjac Glucomanna to polyvinylpyrrolidone and the content of crosslinking agent on the swelling ratio was investigated. Meanwhile, the effect of the degree of the hydrogel crosslinking on the swelling kinetics and the release profiles of the drug in vitro were also examined in pH 2.2 and 7.4. The results showed that the mass ratio of KGM to PVP influenced swelling capability of the hydrogel. That is, the swelling ratio of hydrogel reached to maximum. The swelling ratio and rate of the hydrogel , when the mass ratio of KGM to PVP was close to 1, were increasingly decreased with the increase of the content of crosslinking agent. The mass and rate of controlled release for drug also were increasingly decreased with the increase of the content of crosslinking agent. The hydrogel in pH 2.2 showed better swelling ratio, swelling rate and controlled release for the drug than that of it in pH 7.4.
出处 《宜宾学院学报》 2008年第6期72-75,共4页 Journal of Yibin University
关键词 魔芋葡甘聚糖 水凝胶 缓释 溶胀动力学 Konjae Glucomannan Hydrogel Controlled Release Swelling Kinetics
  • 相关文献

参考文献25

  • 1[1]Jardetzky O.[J].Prog.Biophy.molec.Biol,1996,65(3):171-219.
  • 2[2]Garret D F,Susan D R,Nitya P K,et al.[J].Macromolecules,1997,30 (20):6174 -6184.
  • 3[3]Bezemer J M,Radersma R,Grijpma D W,et al.[J].J Controlled Release,2000,64 (1 -3):179 -192.
  • 4[4]Sinha VR,Kumria R.[J].Int.J Pharm,2001,224 (1-2):19-38.
  • 5[5]M.Y.Abdelaal,E.A.Abdel-Rezik,E.M.Abdel-Bary,et al.[J].Appl.Polym.Sci,2007,103:2864-2874.
  • 6[6]M.George,T.E.Abraham.[J].Int.J.Pharm,2007,335:123-129.
  • 7[7]ShiuChih Wang,BingHung Chen,LiFang Wang,et al.[J].Int.J.Pharm,2007,329(1 -2):103 -109.
  • 8[8]Ulf Siemoneit,Christoph Sehmitt,Carmen Alvarez-Lorenzo,et al.[J].Int.J.Pharm,2006,312(1-2):66-74.
  • 9[9]Hasan Basan,M.Tevfik Orbey.[J].Eur J Pharm.Biopharm,2007,65:39-46.
  • 10[10]J Liesiene,J Matulioniene.[J].React.& Funct.Polym,2004,59:185-191.

二级参考文献2

共引文献2

同被引文献103

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部